Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
12h
GlobalData on MSNFDA puts clinical hold on BioNTech’s malaria vaccine trialThe FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technologyâ„¢ platform to rapidly optimize and derisk drug discovery and development, ...
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results